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Precision cardio-oncology: understanding the cardiotoxicity of
cancer therapy
Xinqiang Han1, Yun Zhou2 and Wendi Liu3
Current oncologic treatments have brought a strong reduction in mortality in cancer patients. However, the cancer therapy-related
cardiovascular complications, in particular chemo-therapy and radiation therapy-induced cardiotoxicities are a major cause of
morbidity and mortality in people living with or surviving cancer. The simple fact is that all antineoplastic agents and radiation
therapy target tumor cells but also result in collateral damage to other tissues including the cardiovascular system. The commonly
used anthracycline chemotherapy agents can induce cardiomyopathy and congestive heart failure. Targeted therapies with human
epidermal growth factor antibodies, tyrosine kinase inhibitors or vascular endothelial growth factor antibodies, and the
antimetabolites also have shown to induce cardiomyopathy and myocardial ischemia. Cardiac arrhythmias and hypertension have
been well described with the use of tyrosine kinase inhibitors and antimicrotubule agents. Pericarditis can happen with the use of
cyclophosphamide or cytarabine. Mediastinal radiation can cause constrictive pericarditis, myocardial ﬁbrosis, valvular lesions, and
coronary artery disease. Despite signiﬁcant progresses in the understanding of the molecular and pathophysiologic mechanisms
behind the cardiovascular toxicity of cancer therapy, there is still lack of evidence-based approach for the monitoring and
management of patients. This review will focus mainly on the recent advances in the molecular mechanisms of cardiotoxicity
related to common cancer therapies while introducing the concept of cardio-oncology service. Applying the general principles of
multi-disciplinary approaches toward the diagnosis, prevention, monitoring, and treatment of cancer therapy-induced
cardiomyopathy and heart failure will also be discussed.
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INTRODUCTION
Heart disease and cancer are the top two causes of mortality
globally, accounting for 46.1% of deaths worldwide.1, 2 Cardio-
vascular complications of cancer therapy signiﬁcantly contribute
to the global burden of cardiovascular disease (CVD). Congestive
heart failure (CHF) in particular is a relatively common and life-
threatening complication. While contemporary cancer treatment
truly represents a medical success story because 5-year survival
rates for all malignancies have increased from 50% in the
1975–1997 period to 68% in the 1998–2005 period,3 this success
has produced a large cohort of cancer survivors with increased risk
of chronic multi-systemic diseases.4 In 2014 there were ~14.5
million American cancer survivors5 and the number is anticipated
to reach 18 million by 2020.6 In Europe ~3 million patients are
diagnosed with cancer each year, which means there is a large
group at risk of treatment-related complications.7 Improved
survival is often accompanied by treatment-related complications,
including adverse effects of cancer therapies on the heart. Cancer
therapies including cytotoxic chemotherapies, molecularly tar-
geted therapies, and mediastinal irradiation have been linked to
myocyte damage, left ventricular systolic and diastolic dysfunc-
tions, CHF, thrombogenesis, pericardial disease, hypertension,
myocardial ischemia, cardiac arrhythmias, and vasospasm.8, 9 In
particular, CHF as a result of cancer therapy has been linked to a
3.5-fold increased mortality risk compared with idiopathic
cardiomyopathy.10 In the long term, the risk of death from CVD
may exceed the risk of recurrence for many forms of cancer.11, 12
For most cardiologists the CVD of cancer survivors are managed
just like the patients with chronic comorbidity such as diabetes or
hypertension rather than a terminal illness, except such manage-
ments can be considerably more challenging. Not infrequently,
when a cardiac patient develops a malignancy the cardiologist
loses interest for pursuing further diagnosis that may lead to
appropriate intensive treatment and/or intervention possibilities.
Conversely, failure to predict the long-term consequences of
cancer treatment–associated cardiovascular complications leads
to under-diagnosis or over-diagnosis of CVD, sometimes resulting
in ineffective prevention of the adverse events and sometimes to
inappropriate interruption of a potentially lifesaving treatment. As
a consequence the management of those patients may be
inadequate, and most importantly, the patients feel left alone and
unprotected. Adding to the complexity is the ever-expanding
number of cancer therapies targeting novel kinases, as well as
other speciﬁc cellular and metabolic pathways that are being
developed and tested in oncology clinical trials. Some of these
drugs may impact the cardiovascular system in detrimental means
while others perhaps in beneﬁcial ways. Despite development of
the new interdisciplinary area of cardio-oncology within the past
two decades,13 patients demand and deserve better quality of
care from cardiologists and oncologists. While there is no perfect
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deﬁnition, the term cardio-oncology or onco-cardiology we use in
this paper describes the integrative and translational medicine
between cardiologists and oncologists focusing on the diagnosis,
prevention, and management of cardiovascular complications
associated with the development and treatment of malignancy. A
schematic drawing of the current cardio-oncology service with its
interactive subspecialties, as well as major referrals is illustrated in
Fig. 1 which will be referred to and discussed throughout the
review. In the era of personalized or precision medicine with
exploding information from translational investigations of mole-
cular and genetic targets, close interactions between the two
specialties are mandatory for the optimization of anti-cancer
therapies, cardiovascular complication prevention, and drug
discovery. The following discussion will focus mainly on the
molecular mechanisms of common cancer therapy related
cardiotoxicity and the principles of multi-disciplinary approaches
to the diagnosis, prevention, monitoring, and treatment of the
cardiovascular complications related to cancer therapy. A detailed
review of the precision oncology aspects of the cancer therapy
agents is beyond the scope of this manuscript, and wherever
appropriate and relevant, updated references will be cited.
CARDIOVASCULAR COMPLICATIONS OF CANCER THERAPY:
MOLECULAR TARGETING
The most recent ESC guideline broadly divides the cardiovascular
complications of cancer therapy into nine major categories14
pertaining to either the cardiac or the vascular system. The cardiac
complications encompass myocardial dysfunction and CHF,
coronary artery disease, valvular heart disease, arrhythmias, and
pericardial diseases. The vascular complications would include
arterial hypertension, thromboembolic event, peripheral vascular
disease and stroke, and pulmonary hypertension. The cardiac
toxicity of antineoplastic agents can be addressed from four
aspects: direct cytotoxic effects of chemotherapy and associated
myocardial dysfunction, cardiac ischemia, cardiac arrhythmias, and
pericarditis. Radiation therapy can also lead to coronary artery
disease and ﬁbrotic changes to the valves, pericardium, and
myocardium. In the following we will focus our discussions on the
cardiotoxicity relating to different classes of cancer therapies and
the underlying cellular, as well as molecular mechanisms which
are brieﬂy summarized in Table 1. Readers are also referred to a
number of excellent reviews summarizing the cardiovascular toxic
effects of the targeted immunotherapies.15, 16
Anthracycline cardiotoxicity
Elucidation of the cellular and molecular mechanisms of
anthracycline cardiotoxicity takes time and multi-disciplinary
efforts. Daunorubicin was the ﬁrst anthracycline with cardiotoxi-
city being reported half a century ago.17 In the original study, of
the 19 children of solid tumors or acute leukemia who received
daunorubicin at a cumulative dose of 25 mg/kg and higher 14
died after 1 week up to 9 months. “Seven, prior to death,
developed cardiopulmonary symptoms characterized by tachy-
cardia, with or without arrhythmia, gallop rhythm and in some
cases CHF, tachypnea and in some cases dyspnea”.17 The
discovery and application of other anthracycline chemotherapies
and the demonstration of dose-dependent probability of CHF in
the 1970s18, 19 were perhaps the ﬁrst event to foster partnership
between oncologists and cardiologists. Since then, efforts to
reduce anthracycline-induced cardiotoxic effects through dose
limitation, chemical protection, change in formulation, or change
in delivery schedule have been consistently made.20 Two types of
cardiotoxicity were described: acute reaction which usually occurs
during or shortly after chemotherapy and chronic response which
develops months, years, or decades after completion of therapy.
Acute cardiotoxicity mainly presented as electrocardiographic
changes and/or cardiac arrhythmias.17, 21–24 The incidence of CHF
as a result of chronic toxicity of anthracycline treatment varied
from 3–30%, largely owing to differences in the patient
populations studied, clinical criteria including systolic and diastolic
or both deﬁned, and accumulative doses used.17, 21–24 Myocardial
injury can occur unpredictably with doses as low as 200 mg/m2,
and the incidence increases steeply as doses exceed 550 mg/m2.
The delayed manifestation of chronic cardiotoxicity can be a
signiﬁcant challenge as many patients might not receive regular
preventive surveillance or timely management at the early stage
of disease development which may be reversible with effective
interventions. Currently there is still a lack of guideline or
standardized risk stratiﬁcation recommendation despite a growing
number of cancer survivors are at increased lifetime risk of
anthracycline-induced cardiotoxicity.
Several mechanisms have been proposed to explain the
anthracycline (using doxorubicin, Dox, as an example) cardiotoxi-
city but one of the commonly accepted explanations is the
oxidative stress which generates reactive oxygen species (ROS)
and oxygen free radicals (OFR) during oxidative respiratory chain
reaction in the mitochondria. Metabolism of Dox can generate
excessive ROS such as superoxide, hydrogen peroxide, the
reactive nitrogen species (RNS), as well as other OFR that are far
beyond the clearance capacity of the antioxidant-producing
Fig. 1 Cardio-oncology service with major interactive specialties and common referrals
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enzymes (such as peroxidase, catalase, and superoxide dismutase)
and the metabolism by NADPH dehydrogenase, cytochrome P-
450 reductase, and xanthine oxidase. The resulting damages to
DNA, RNA, proteins, and membrane lipids from ROS, RNS and OFR
lead to cardiomyocyte death. Apoptosis, necrosis, and autophagy
all can be involved during generation of ROS and lipid
peroxidation but the role of autophagy in Dox-mediated cell
death is still controversial.24, 25 Both ROS and RNS can affect ion
channel proteins including several K+ currents causing action
potential propagation abnormality and cardiac arrhythmias.26 OFR
also inhibits calcium sensor proteins in the excitation-contraction
coupling causing myocardial stunning.27 Heart as a pumping
organ would require large amount of energy generation and
turnover to support its physiological function. As such the
mitochondria which are rich in cardiac myocytes has been
identiﬁed as the major subcellular target in doxorubicin-induced
cardiotoxicity (see Fig. 2). Iron has been shown to play an
important role in this process.28, 29 Dox is known to chelate free
iron to form iron–Dox complexes which react with oxygen and
trigger ROS production and lipid peroxidation.30 Dox-dependent
iron overload is compartmentalized as iron preferentially accu-
mulates in cardiac mitochondria. Despite this well-established
close association of anthracyclines, free iron, and activation of
ROS, accumulating data demonstrate that neither anti-oxidants
nor some iron chelators can provide therapeutic beneﬁts in
preclinical models and clinical trials.31–33 Of those iron chelators
tested only dexrazoxane appears to be more promising34–36 in
both breast cancer patients and children with high risk acute
lymphoblastic leukemia. Dexrazoxane has shown a signiﬁcant
cardioprotective effect as measured by both noninvasive testing
(multiple-gated acquisition (MUGA) scan) for systolic function and
improvement in clinical CHF symptoms, although the time to
disease progression and the long-term event-free survival appear
to be not affected.37, 38 This clearly suggests existence of ROS/
Iron-independent mechanisms for anthracycline cardiotoxicity.
Dexrazoxane, the only Food and Drug Administration (FDA)
approved effective protectant against anthracycline cardiotoxic
effects, was shown to be a catalytic inhibitor of topoisomerase II
(TopII).39 There are two TopII isozymes. TopIIα, highly expressed in
cancer cells and required for cell division, is the target for
anthracycline’s antitumor effect.40–42 However, adult cardiomyo-
cytes express only TopIIβ, which is not required for cell division.43
Since dexrazoxane binds to TopIIβ and inhibits Dox-induced DNA
double-strand break, it is likely that Dox causes cardiotoxic effects
by targeting TopIIβ in cardiomyocytes.39 By binding to TopIIβ in
the nucleus and stabilizing this enzyme, Dox causes continuous
DNA breakdown and prevents the broken DNA double helix from
repairing. Dox-induced DNA double-strand breaks and apoptosis
through the p53 pathway activation. This effect could be blunted
in a mouse model in which TopIIβ was genetically deleted.39, 44 In
addition to nuclear TopIIβ, cardiomyocytes also express mitochon-
drial topoisomerases including TopIIβ, TopIIIα, and TopImt. TopImt
is the mitochondria speciﬁc isoform and important for protecting
mitochondria DNA from damage. TopImt knock-out mice are
signiﬁcantly more sensitive to doxorubicin cardiotoxicity and
exhibit marked mitochondrial dysfunctions including impaired
respiratory chain protein production and mitochondrial cristae
ultrastructure organization, along with decreased O2 consumption
and increased ROS production, eventually leading to advanced
CHF and increased mortality.45 While doxorubicin traps nuclear
TopIIβ cleavage complexes, resulting in mitochondrial DNA
damage and cardiac dysfunction, TopImt is cardioprotective as it
maintains normal mitochondrial DNA homeostasis and enables
mitochondrial DNA to be replaced (Fig. 2).
The demonstration of the molecular targets including TopIIα,
TopIIβ, and TopImt which are all related to anthracycline therapy
has signiﬁcant pharmaceutical and clinical implications: First, it
provides the rationale for developing TopIIα-speciﬁc anticancer
drugs to prevent other tissue toxicities (i.e., cardiotoxicity) in
patients receiving anthracycline-based chemotherapy. Drugs that
speciﬁcally target the TopIIα isozyme, but not TopIIβ or TopImt
should be less cardiotoxic and, hence, more useful clinically.
Second, patients with higher expression of TopIIβ in cardiomyo-
cytes may be more susceptible to anthracycline-induced cardio-
toxicity. Judicious recommendation of genetic and molecular
testing could have a potential role in risk-stratifying patients when
selecting anthracycline based chemotherapy regimen. Thirdly, in
those high risk patients including who (1) express high levels of
cardiac TopIIβ and low levels of TopImt, (2) will need higher total
dose or prolonged maintenance anthracycline therapy, and (3) will
need additional cardiotoxic agents, selective co-administration of
the protective agent dexrazoxane could be more beneﬁcial.
HER2-targeted cancer therapy cardiotoxicity
Overexpression of human epidermal growth factor receptor 2
(HER2/ErbB2) in breast cancer is a poor prognostic indicator, as
these tumors tend to be more aggressive and associated with
higher recurrence rates.46 Trastuzumab (Herceptin), a humanized
anti-HER2 monoclonal antibody targeting the extracellular domain
of this receptor, has been shown in both the metastatic47 and the
Table 1. Common anticancer therapies and their molecular
mechanisms of cardiotoxicity
Anticancer
therapies
Molecular mechanisms of cardiotoxicity
Anthacyclines Activate Necleus TopIIβ (inhibited by
Dexrazoxane)
Generate ROS
Activate TopImt
Fe2+ overload (chealated by Dexrazoxane)
Damage transcription
Energy depletion
Prevent DNA repair
Alkylating agents Cause endothelial dysfunction
Cause thrombosis
Direct DNA damage
HER2/ERB2 Ab Inhibit Pro-Survival NRG-1/ErbB Pathway
Generate ROS
TKIs/VEGFR Ab Inhibit angiogenesis
Cause endothelial dysfunction
Cause energy depletion
Antimetabolites Inhibit angiogenesis
Cause endothelial dysfunction
Cause energy depletion
Generate ROS
Antimicrotubules Inhibit microtubule formation
Activate NCS-1 causing Ca2+ overload
Radiation therapy Inhibit angiogenesis
Cause endothelial dysfunction
Cause energy depletion
Generate ROS
TKIs tyrosine kinase inhibitors, VEGFR vascular endothelial growth factor
receptor, NRG-1 neuregulin-1, HER2/ErbB2 human epidermal growth factor
receptor 2, Ab antibody, TopImt mitochondrial topoisomerase I, TopIIβ
topoisomerase IIβ, ROS reactive oxygen species, NCS-1 neuronal calcium
sensor 1
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adjuvant48 setting to dramatically change the survival in HER2
positive breast cancer. The molecular mechanisms of HER2/
ErbB2 signaling and related anticancer action have been well-
reviewed.49, 50 These receptor (ErbB2/ ErbB4) are also expressed in
cardiomyocytes.51 Activation of this pathway by growth factor
neuregulin-1 (NRG-1) plays a protective role against myocardial
stress.51, 52 The binding of anticancer drugs to HER2 receptor may
disrupt this cardioprotective pathway and result in cardiotoxicity
(Fig. 2). Clinical trials in the adjuvant setting reported CHF in 1.7 to
4.1% and left ventricular dysfunction in 7.1 to 18.6% of patients
receiving trastuzumab, although in practice, incidence may be
higher.53 Interestingly, emerging evidence also indicates that this
pathway is critically involved in mechanisms of anthracycline
cardiotoxicity. Mice with cardiac-speciﬁc overexpression of ErbB2
had a lower level of mitochondrial and whole heart ROS, as well as
less myocyte death after isolation. Cultured H9C2 cardiomyocytes
transfected with ErbB2 showed less cellular toxicity and produced
less ROS after doxorubicin treatment.54 Mice with a ventricular-
restricted deletion of ErbB2 (ErbB2−/−) develop chamber dilation,
wall thinning and decreased contractility. Cardiomyocytes from
these ErbB2−/− mice are more sensitive to Dox-induced cell
death.55 Similarly, worsening left ventricular systolic function and
survival were seen in mice when the neuregulin-1 gene was
knocked out, and this is associated with the depressed activation
of the ErbB2 receptor.56 Thus, inhibition of the pro-survival NRG-1/
ErbB pathway provides a possible explanation to the ﬁnding that
combinations of anthracyclines (e.g., doxorubicin) and anti-ErbB
monoclonal antibodies (e.g., Herceptin) enhance antitumor
efﬁcacy but cause more pronounced cardiotoxicity than either
treatment alone. However, there are noticeable differences
between the anthracycline and trastuzumab cardiotoxicity: Unlike
anthracyclines, there is no relationship between the accumulative
dosage of trastuzumab and the probability of cardiotoxicity which
is usually reversible upon cessation of drug administration and/or
initiation of guideline directed medical therapies for cardiomyo-
pathy (such as β-blockers and ACE-I). This information is clinically
relevant as combination therapy using anthracyclines and
monoclonal antibodies targeting ErbB2 is currently the standard
of care for breast cancer patients who are HER2-positive: Adding
trastuzumab to adjuvant Dox chemotherapy has signiﬁcantly
decreased the breast cancer recurrence risk by 50%, and mortality
by 30% in HER2-positive patients. Thus, for clinical cardio-
oncologists optimized treatment strategies should be developed
to minimize the cardiotoxicity without signiﬁcantly compromising
its therapeutic beneﬁt. Treatment duration can be adjusted and
clinical responses including potential cardiotoxicity should be
carefully monitored. Because the inhibition of HER2 signaling by
trastuzumab in patients receiving Dox may interfere with the
protective effects of NRG-1 on the anthracycline-damaged
myocardium (see Fig. 2), the most-effective means to limit the
cardiotoxicity is to modulate the dosages and prolong the time
between Dox and trastuzumab by at least 90 days.57, 58
Alkylating agents related cardiotoxicity
Alkylating agents including nitrogen mustards (i.e., cyclopho-
sphamide and ifosfamide) and the platinum-containing molecule,
cisplatin, are the oldest class of anticancer agents. They exert their
action via binding to negatively charged DNA sites, causing DNA
strand breaks and DNA strand cross-linking.59 Cyclophosphamide
is a prodrug which upon activation forms an alkylating molecule
that binds to DNA and causes inter-strand and intra-strand DNA
breaks (Fig. 2). Manifestations of cyclophosphamide-induced
cardiotoxicity include pericardial effusions, myocarditis, pericardi-
tis, and heart failure which is irreversible in 25% of cases at a doses
of ≥ 1.55 g/m2/day. Left ventricular dysfunction develops in 7 to
28% of patients and may be dose related, occurring shortly after
initial administration.60 Known risk factors include total bolus
dose, older age, combination therapy with other cancer drugs and
mediastinal radiation.61 In addition to vascular events such as
deep vein thrombosis and pulmonary embolism, cisplatin treat-
ment is also associated with both acute and late-onset
cardiotoxicity. Acute myocardial infarction, angina pectoris, and
cerebrovascular ischemia are relatively uncommon, occurring in
~2% of patients.62 Likely pathophysiology is multifactorial
including procoagulant and direct endothelial toxic effects, as
well as hypersensitivity reactions occurring during treatment.
Patients could also develop subclinical abnormality in systolic
dysfunction with incidence rates of 6 and 33%, respectively, 10 to
20 years after initial treatment.63
Antimetabolites and antimicrotubule agents related cardiotoxicity
In cancer patients treated using 5-ﬂuorouracil (5-FU) containing
regimen, cardiac symptoms generally occur early during the drug
Fig. 2 Mechanisms of cardiovascular injuries from commonly used cancer therapies. Common cellular targets and pathophysiological
pathways are schematically illustrated. Red arrows denote detrimental effects; Blue arrows imply protective effects. The eventual death of
cardiomyocytes and endothelial dysfunction lead to various cardiovascular complications. Refer to text for detail. Abbreviations: TKIs tyrosine
kinase inhibitors, VEGF vascular endothelial growth factor, NRG-1 neuregulin-1, HER2/ErbB2 human epidermal growth factor receptor 2, R
receptor, TopImt mitochondrial topoisomerase I, TopIIβ topoisomerase IIβ, ROS reactive oxygen species, NCS-1 neuronal calcium sensor 1, SR
sarcoplasmic reticulum, ACS acute coronary syndrome
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infusion. A meta-analysis reported an incidence of symptomatic
cardiotoxicity of 1.2 to 4.3% during treatment with 5-FU and
suggested that the risk can be increased by continuous infusion
and concurrent treatment with alkylating agent cisplatin.64 The
most common symptom, the typical angina pectoris is reversible
but myocardial infarctions have also been reported.65 5-FU
cardiotoxicity is relatively infrequent, independent of dosage,
and may be related to a continuous infusion schedule. The
presence of cardiac risk factors is not predictive.66 The pathogenic
mechanism of cardiovascular toxicity associated with 5-FU is not
completely understood; however, coronary thrombosis, arteritis,
and vasospasm have been proposed as possible explanations.
Additional hypothesized mechanisms are direct toxic effects of the
drugs on the myocardium, interaction with the coagulation
system, and autoimmune responses.67 5-FU can induce apoptosis
and autophagy through the production of oxidative stress in
cardiomyocytes and endothelial cells.68 In animal model the
cardiotoxicity from 5-FU and capecitabine was found to be
associated with the formation of ROS, lipid peroxidation, and a
rapid depletion of glutathione; the resulting increase in oxidative
stress was associated with mitochondrial dysfunction (Fig. 2),
which triggered caspase-3 activation and led to apoptosis or
necrosis.68 Other studies have also shown that 5-FU can induce
dose and time-dependent depletion of high energy phosphates in
myocardial cells.69–71 In 5% of patients treated with paclitaxel,
atrioventricular block, left bundle branch block, ventricular
tachycardia, and ischemic cardiac events were observed, whereas
asymptomatic bradycardia occurred in a variable proportion of
patients (from < 0.1 to 31%).8, 72 Arrhythmias and conduction
disorders were likely mediated by an effect of paclitaxel to
accelerate spontaneous calcium release in cardiomyocytes
through interacting with the neuronal calcium sensor 1, a calcium
binding protein that is known to regulate the inositol-1,4,5-
trisphosphate receptor.73 While paclitaxel itself rarely causes CHF,
the combination of paclitaxel with anthracycline therapy does
facilitate the anthracycline-associated cardiotoxicity, likely due to
reduced anthracycline elimination resulting in higher plasma drug
accumulation.74
Tyrosine kinase inhibitors (TKI) and Vascular endothelial growth
factor (VEGF) antibody related cardiotoxicity
VEGF is the main member of a family of seven structurally and
functionally related cytokines (VEGF-A, VEGF-B, VEGF-C, VEGF-D,
VEGF-E, VEGF-F, and placental growth factor. These molecules play
a critical role in angiogenesis, cell survival, growth, and prolifera-
tion of endothelial cells by binding to speciﬁc receptors including
VEGFR-1, VEGFR-2, VEGFR-3, and neuropilin.75 VEGF-A is the most
representative compound and its mRNA is expressed in several
tissues including the heart. VEGFR-2 is the most important
receptor in mitogenesis signaling. VEGF signaling is known to
play an essential role in cancer growth, invasion, and angiogen-
esis. Readers are also referred to the excellent reviews regarding
the cellular and molecular mechanisms of TKI and anti-VEGF
therapies.76, 77 This pathway has emerged as an important target
in cancer drug development over the past decade. As such, anti-
VEGF treatments including speciﬁc VEGF antibodies and VEGFR
TKIs are currently the standard of care for several malignancies.
Such small molecules are characterized by a targeted action78 on
well-known proteins with important roles in cancer biology.
Unfortunately, despite their “selective” action they can still cause
cardiovascular complications such as arterial hypertension (HTN),
QT interval prolongation, CHF, cardiomyopathy, stroke, acute
myocardial infarction, thromboembolic events and cardiovascular
deaths.79, 80 While characterization of the detailed, complex
molecular mechanisms of anticancer actions of TKIs and VEGF
antibodies is beyond the scope of this review (as many signaling
molecules may be involved), TKI and VEGF antibody-induced
cardiotoxicity can be recognized by both on-target (inhibiting
VEGFR) and off-target (inhibiting other targets unrelated to VEGFR)
mechanisms.
Sunitinib, an orally given small-molecule TKI commonly used to
treat renal malignancies, has a long-term CHF cumulative
incidence of 1.5–4.1%.81 The real-world experience is in fact
worse, with ≈14% of patients experiencing a > 10% decline in
ejection fraction.82 Meta-analysis from 4679 patients in 10
randomized controlled trials treated with VEGFR TKIs reported
15% deaths from myocardial infarction among all fatal adverse
events (FAE) which occurred at 1.5%, and two fatal CHF cases,
although hemorrhage was the most frequently (47.5%) occurring
FAE.83 Both sunitinib and sorafenib can block multiple tyrosine
kinase receptors, making it difﬁcult to identify the on-target
mechanism(s) of the well-documented side effects including CHF,
hypertension, and intracranial bleeding. An off-target effect of
sunitinib on ribosomal S6 kinase can increase myocyte apoptosis84
leading to heart failure. However, the risk of relatively speciﬁc TKIs
such as axitinib on renal cell carcinoma patients was similar to that
of the relatively non-speciﬁc TKIs (sunitinib, sorafenib, vandetanib,
and pazopanib).85 Sunitinib inhibits angiogenesis by targeting the
tyrosine kinase domain of VEGFR. By blocking the VEGF–VEGFR
signaling pathway (on-target action) sunitinib reduces capillary
density and inhibits the generation of nitric oxide (NO), thus
blunting the vasodilation of NO and leading to hypertension and
myocardial stress. A marked increase in systemic hypertension
results in signiﬁcant increases in the afterload of left ventricle and
myocardial oxygen demand leading to myocardial injury/infarc-
tion and LV systolic dysfunction in vulnerable patients. The
incidence of hypertension has been estimated at 15–47% with
sunitinib and 17–42% in patients treated with sorafenib.86–88
Multiple off-target mechanisms are also recognized with sunitinib
cardiotoxicity. Sunitinib can inhibit the kinase domain of platelet-
derived growth factor receptor and prevent myocytes from
responding to stress by secreting proangiogenic factors.89
Another off-target action of sunitinib, the direct inhibition of
adenosine monophosphate-activated protein kinase (AMPK)
which is a regulator of cardiomyocyte response to stress,90 is
suggested to play a central role in cardiotoxicity since an
adenovirus-mediated gene transfer of an activated mutant of
AMPK reduces sunitinib-induced cell death. CHF may occur as a
result of direct cardiomyocyte mitochondrial damage and
cytochrome C-induced apoptosis.86 In cultured cardiomyocytes,
sunitinib induces loss of mitochondrial membrane potential and
energy depletion90 leading to cardiomyocyte dysfunction (Fig. 2).
QT interval prolongation appears to be another off-target class
electrophysiological effect for some of the TKIs including
sunitinib.91, 92 If inadequately managed, these cardiovascular
effects could further increase the morbidity and mortality of a
high risk patient population.
Bevacizumab is a recombinant monoclonal antibody against
VEGF-A which blocks angiogenesis by inhibiting the binding of
the normal VEGF ligand to its receptor. This agent is approved in
the United States to treat metastatic colorectal cancer, metastatic
nonsquamous, non-small cell lung cancer, renal cell carcinoma,
glioblastoma multiforme, and ovarian cancer. The original
approval of this agent for metastatic colorectal cancer by the US
FDA marked the modern era of antiangiogenic therapy for cancer
patients. Bevacizumab is associated with a small increase in the
risk of LV dysfunction with CHF developing in 1% by bevacizumab
alone and 3% with prior chemotherapy.93, 94 Another meta-
analysis including 3784 patients95 showed that bevacizumab in
metastatic breast cancer increases the risk of grade 3 or 4 CHF
(high grade CHF deﬁned by National Cancer Institute common
toxicity criteria NCI-CTC, version 2 or 3; http://ctep.cancer.gov) by
ﬁve-fold, with an overall incidence of 1.6%. The cardiotoxicity
could be due to antagonism of the VEGF-mediated angiogenesis
and endothelial integrity known to protect cardiac myocytes from
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oxidative stress,96 or HTN which is a class effect of such drugs
reported in every trial involving these inhibitors,97 as precipitation
of underlying cardiac dysfunction.96
Understanding the molecular targeting and cellular mechanisms
of cardiotoxicity of this class of anticancer agents is essential for
clinical cardio-oncologists for effective patient management.
Sunitinib, pazopanib, and especially vandetanib prolong the QT
and therefore increase the risk of Torsades de pointes (TdP), a form
of lethal arrhythmia. These drugs should only be used cautiously in
the presence of a history of QT prolongation or concomitant
antiarrhythmic treatments, bradycardia, or electrolyte abnormal-
ities, while in such conditions vandetanib should be completely
avoided. In the setting of TKI-containing chemotherapy it is also
critical to evaluate the pro-arrhythmic effect of β-blocker therapy
which is usually antiarrhythmic and especially beneﬁcial for CHF
and cardiomyopathy protection, since bradycardia from β-blocker
therapy further promotes development of TdP. Consideration
should also be given to the fact that while HTN develops as the
most common cardiovascular side effect of the anti-VEGF
treatment, and in the case of bevacizumab for metastatic colorectal
cancer patients of which 20% developed grade II-III HTN (systolic
BP≥ 160mmHg), a partial remission was observed in 75% of the
hypertensive but only 32% of the normotensive patients.97 Those
patients with grade II-III HTN also had a signiﬁcantly longer
progression-free survival.98 In the absence of guideline or data
from large randomized controlled trial, individualized therapy must
be formulated by cardio-oncologists to balance the effective
therapeutic actions of these anticancer agents against the severity
of cardiovascular toxicity proﬁle.
Radiation therapy related cardiotoxicity
CVD related to thoracic and mediastinal radiation therapy (RT) of
cancer survivors remains the most common nonmalignant cause
of morbidity and mortality.99 RT is associated with macrovascular,
microvascular, and endothelial injury, valvular dysfunction, ather-
osclerosis, ﬁbrosis, and pericardial disease including effusive or
constrictive pericarditis. Left ventricular dysfunction and CHF can
occur as acute radiation myocarditis but more commonly
develops as a long-term consequence of ﬁbrosis leading to
ventricular dysfunction or restrictive cardiomyopathy.100 Overall,
compared with non-irradiated patients, patients who have
undergone chest radiotherapy have a 2% higher absolute risk of
cardiac morbidity and death at 5 years and a 23% increased
absolute risk after 20 years.101 In general, the tolerance dose of
human myocardium is ~40 Gy.102 Cardiac myocytes are relatively
resistant to radiation damage because of their post-mitotic state.
However, cardiac endothelial cells remain sensitive to radiation,
and the pathophysiology of most forms of radiation-induced
cardiovascular disease (RICD) appears to be associated with
damage to endothelial cells (Fig. 2). Radiation is believed to result
in transient increases in oxidative stress, resulting in formation of
ROSs and a subsequent inﬂammatory response that includes
activation of nuclear factor-kappa B. Upregulation of proinﬂam-
matory pathways results in increased expression of matrix
metalloproteinases, adhesion molecules, and proinﬂammatory
cytokines and downregulation of vasculoprotective nitric oxide.103
Indirect evidence for radiation-induced vascular inﬂammation
comes from numerous studies that demonstrated increased levels
of the proinﬂammatory cytokines interleukin 6, tumor necrosis
factor alpha, and interferon gamma in Japanese atomic bomb
survivors.104
Ischemic heart disease is the most common cause of cardiac
death in patients who have undergone radiation therapy.
Atherosclerotic lesions in RICD are morphologically identical to
those in non-irradiated vessels and are characterized by intimal
proliferation, accumulation of lipid-rich macrophages, and plaque
formation.105 Epidemiologic studies suggest a 40-year cumulative
incidence rate of 24.8% for RICD, and most cases involve
characteristic cardiac insults such as pericarditis, pericardial
ﬁbrosis, valvular disease, coronary disease or myocardial infarc-
tion.106, 107 Profound inﬂammation-induced by radiation injury
results in the development of a diffuse, patchy interstitial ﬁbrosis
of the myocardium, as well as exudate of a variable amount of
neutrophil inﬁltrated and protein-rich ﬂuid within the pericardial
sac. Rapid accumulation of pericardial effusion rarely can cause
cardiac tamponade necessitating urgent pericardiocentesis.
Chronic inﬂammation results in thickening of pericardium and
pericardial adhesion. Clinically, diastolic heart failure or heart
failure with preserved systolic function ﬁrst develops when heart
loses compliance from both myocardial ﬁbrosis and pericardial
thickening/adhesion. Wall motion abnormalities including both
systolic and diastolic dysfunctions were found in 13, 18, and 29%
of patients with a latency of two to 10, 11 to 20, and longer than
20 years after RT, respectively, vs. only 5% in age-matched controls
without a history of irradiation in the Framingham study.108 In an
autopsy series of 27 patients with RICD,109 14 of the 20 (70%)
available pericardium examinations demonstrated signiﬁcant
pericardial diseases (effusions, constrictions or both). In another
necropsy series of 16 patients with known RICD110 pericardial
thickening was found in all cases (100%).
Implementation of dose reducing techniques for RT has
signiﬁcantly reduced the acute pericarditis which usually occurs
days to weeks after therapy at doses higher than 40 Gy. The dose-
dependent (usually≥ 50 Gy), chronic pericarditis is the most
common cardiac complication from RT, which usually occurs from
3 months to over a decade with 1 year being the median time. The
radiation-sparing techniques routinely used nowadays have
dramatically reduced the incidence of symptomatic, chronic,
delayed pericarditis from ~20% in the 1970’s to about 2.5%.111
Dose-volume histogram calculation for the heart, prone position,
and deep inspiration breath hold can all lower the risk of direct
damage to the heart. Radiation is known to induce oxidative stress
with generation of ROS which is thought to play a key role in the
transition from acute inﬂammation to chronic inﬂammation and
ﬁbrosis.112 These radiation-sparing measures may also prevent the
additive or synergistic effect of ROS with other cancer therapy
agents such as anthracyclines and antimetabolites as discussed
above.
MULTI-DISCIPLINARY APPROACHES TOWARD
INDIVIDUALIZED CARDIO-ONCOLOGY CARE
Guideline directed principles113–115 of diagnosis, prevention, and
treatment should be followed with particular attentions paying
toward individual patient clinical proﬁles including age, gender,
pre-existing cardiovascular risk factors, type of cancers and
treatment regimen. Clear communication among a large multi-
disciplinary team (Fig. 1) including cardiologists, oncologists,
imaging specialists, clinical pharmacologists, the patient, and their
family is essential for many life-modifying decisions, and this often
requires periodic reconsideration during a course of therapy.
Adding to the complexity is the fact that many decisions must be
based on limited evidence, and in the context of rapidly evolving
cancer therapeutics, experience and expert opinion become
increasingly important. Cardio-oncology care should include
primary prevention of cardiovascular complications in “high risk”
patients with aggressive risk factor modiﬁcations and ongoing
monitoring early toxicities, effective treatment of complications
that have already developed and active prevention of worsening
complications, pre-operative assessment of cardiovascular risks for
cancer surgeries, and investigation of possible cardiac invasion
from malignancy. A multi-disciplinary approach to the manage-
ment of cardiomyopathy and CHF in cancer therapy patients will
be elaborated below.
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Cardiomyopathy and CHF
Cardiomyopathy implies structural heart abnormalities. CHF is a
clinical syndrome characterized by typical signs and symptoms.113
According to American College of Cardiology/American Heart
Association/Heart Failure/Society of America guideline staging,114,
115 symptomatic ventricular dysfunction is often an avoidable late
stage in a chronic process including cancer-related treatment (Fig.
3). Overwhelming evidence supports the notion that CHF can be
prevented and the onset delayed by modifying risk factors (stage
A) for CHF and treating asymptomatic left ventricular systolic
dysfunction (stage B). Because the diagnostic suspicion relies on
clinical symptoms and signs, medical history and physical
examination continue to be vital. CHF can be further classiﬁed113
into heart failure with preserved EF (HFpEF), heart failure with
medium range EF (HFmrEF), and heart failure with reduced EF
(HFrEF), according to the left ventricular ejection fraction (LVEF).
Diagnostic modalities
The ﬁrst step in preventing heart failure should be a careful clinical
assessment of modiﬁable and non-modiﬁable risk factors, during a
comprehensive clinical assessment. During any baseline assess-
ment, it is also important to clarify the cancer therapy that is
planned by the oncology team. Diagnostic workup includes
biomarkers and imaging modalities. Myocardial injury from cancer
treatment-induced cardiotoxicity releases cardiac troponins which
can be detected long before any reduction in LVEF has occurred.
In a multicenter study116 of breast cancer patients undergoing
doxorubicin and trastuzumab therapy, the associations of 8
biomarkers including the ultrasensitive troponin I (TnI), high-
sensitivity C-reactive protein (CRP), N-terminal pro–B-type
natriuretic peptide (NT-proBNP), growth differentiation factor-15,
myeloperoxidase (MPO), placental growth factor (PlGF), soluble
fms-like tyrosine kinase receptor (sFlt)-1, and galectin (gal)-3 with
the successive development of cardiotoxicity were analyzed. The
most important risk of cardiotoxicity was associated with TnI
change in absolute values. The risk of cardiotoxicity was 46.5% in
patients with the largest changes in both TnI and MPO. Increased
brain-type natriuretic peptide (BNP) levels can detect
chemotherapy-induced LV dysfunction in both adult and pediatric
populations.117, 118 Although signiﬁcant controversies exist
regarding the predictive value of BNP since many studies failed
to ﬁnd a correlation between the level of BNP and the degree of
reduced LV systolic function (HFrEF), this biomarker (BNP or NT-
ProBNP) is required in the new ESC guideline for the diagnosis of
HFpEF and HFmrEF.113 Regarding the diagnostic imaging tests,
transthoracic echocardiography (TTE) is the method of choice for
determining systolic and diastolic function in patients with HF.
Two dimensional (2D) and especially Doppler strain imaging can
reliably detect myocardial deformation variations which may
develop early during anticancer therapy. The speckle tracking
imaging can most accurately measure the reduction in peak
systolic global longitudinal strain which usually precedes the
development of systolic dysfunction and syndromic CHF. Three
dimensional (3D) echocardiography can detect subtle changes in
LV dysfunction that could be missed by 2D study. Cardiac
magnetic resonance imaging (MRI) is considered the gold
standard for the evaluation of the volume, mass, and EF of both
ventricles, and the preferred method for imaging the right
ventricle and for patients with complex congenital heart disease.
It is the best imaging method to detect sub-endocardial damage
and myocardial ﬁbrosis. In particular cases such as patients with
older models of implantable devices (deﬁbrillators, pacemakers
etc.) when MRI is contraindicated, single-photon emission
computed tomography, positron emission tomography, and
noninvasive coronary angiography with multidetector computed
tomography can be useful. Historically, MUGA radionuclide
imaging formed the mainstay of cardiac monitoring in patients
receiving potentially cardiotoxic therapy. While it can reproducibly
measure LVEF than 2D-TTE,119 and reductions during chemother-
apy have been associated with adverse outcome, it may result in
signiﬁcant cumulative radiation exposure (~10mSv per study) yet
provides only limited information on cardiac structure and
diastolic function, thus limiting repeated imaging.
Treatment of heart failure from stage A to D
In Stage A, all risk factors should be aggressively treated. Many
trials show that control of hypertension will delay the onset of CHF
and some also show that it will prolong life.120–122 This is
especially important in cancer patients treated or to be treated
with anti-VEGF regimen which is known to cause signiﬁcant
treatment-related HTN. Other conditions that may lead to or
contribute to CHF, such as obesity, sleep apnea, diabetes mellitus,
hyperlipidemia, and tobacco use should be controlled. The
cardiotoxicity of known chemotherapy agents should be carefully
evaluated at this stage. In cancer patients with known family
history of familial cardiomyopathy (usually at relatively young age)
genetic testing might be considered. In those with known disease
gene carriers less cardiotoxic chemotherapy regimen with closer
monitoring of cardiotoxicity should be adopted. If structural
damage has already occurred (stage B), guideline recommended
Fig. 3 Stages in the development of heart failure. Abbreviations: HF, heart failure; w/o, without; HTN, hypertension; DM, diabetes; MI,
myocardial infarction; LVH, left ventricular hypertrophy; SOB, shortness of breath; DOE, dyspnea on exertion. Modiﬁed from ref.114, 115
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β-blocker, ACE-I or Angiotensin Receptor Blocker (ARB) should be
administered in the absence of contraindication. Treatment of
symptomatic patients with signiﬁcant structural heart damage
(stage C) should include all options for stages A and B plus
aldosterone receptor antagonists, as well as the combination of
hydralazine and isosorbide dinitrate, and the judicious use of
diuretics and digoxin. Patients in stage C disease may beneﬁt
more from a combination drug Entresto (a neprilysin inhibitor,
sacubitril, and an ARB, valsartan) than the traditional ACE-I or ARB.
Critical decision will need to be made about continuation or
withholding of chemotherapy after carefully balancing the risks of
avoiding cancer treatment against further cardiac toxicity. Sudden
death risk in patients with stages B and C disease on optimal
medical treatment should be discussed, and in those patients with
favorable long term survival (≥ 1year) implantable cardioverter
deﬁbrillator can be recommended. Resynchronization therapy
should also be considered in the above stage C patients with a
reasonable survival ≥ 1 year. If patients are progressing to stage D
disease (may also be called “refractory”, “advanced”, or “end-
stage”) treatment options are primarily of ﬂuid restriction,
inotropic agents, mechanical circulatory support, heart transplan-
tation (HT), and palliative or “end-of-life” care. Regarding heart
transplant, the outcomes of 232 chemotherapy related cardio-
myopathy patients had similar 1-year, 2-year, and 5-year survivals
(86 vs. 87%, 79 vs. 81%, and 71 vs. 74%; P = .19) comparing with
other non-ischemic cardiomyopathy patients,123 despite a higher
rate for post-transplant infection (22 vs. 14%, p = 0.04) and
malignancy (5 vs. 2%, p = 0.006) in the chemotherapy-induced
cardiomyopathy group. In the most recent ISHLT position paper
no speciﬁc cancer-free interval is recommended before listing for
HT, as long as the chance of tumor recurrence is deemed low with
negative metastatic work-up.124 Due to the extremely poor
survival125, 126 with 1 year mortality of ~90% or higher, aggressive
chemotherapy for cancer patients with stage D heart failure on
inotropic agents likely offers no beneﬁt. Discussions of individua-
lized care plans with active involvements of family members and
social worker supports usually result in high patient’s satisfaction.
At any stage, the key to successful management is the close
collaboration between cardiologists and other experts, including
primary oncologists, general practitioners, pharmacists, dieticians,
physiotherapists, psychologists, palliative care providers, and
social workers113–115 (Fig. 1).
CONCLUSIONS
This review has highlighted the increasing importance of CVD
management in cancer patients, with particular attention toward
understanding the molecular and cellular mechanisms of cardio-
vascular toxicity from cancer therapy, and emphasized the
important role of multi-disciplinary cardio-oncology service team
in this complex and evolving process. While contemporary cancer
treatment strategies have resulted in dramatic improvement of
patients surviving a diagnosis of cancer for many years, such gain
in quantity, as well as quality of life may be offset by the mortality
and morbidity from therapy-related side effects on the cardiovas-
cular health. Unfortunately the spectrum of cardiovascular
complications associated with the ever-changing cancer therapy
is not expected to decrease in the foreseeable future. Burden of
heart failure after cancer treatment remains excessively high, and
even the most advanced level of cardiac care offered to these
patients remains suboptimal. This is at least in part due to the
challenge from a number of factors somewhat unique to the ﬁeld,
including the complex and growing array of malignancies, novel
anti-cancer agents, new cardiac imaging modalities, absence of
targeted cardioprotective treatments, and lack of coordinated care
of patients with cancer and CVDs. How can we accurately predict
an individual patient’s cardiotoxicity with “standard of care”
chemotherapy regimen remains to be the most challenging
question, among others such as the optimal strategy for
cardiotoxicity monitoring and management. As such, future
evidence-based research to improve the care of patients of
cancer survivors should focus on the following areas: (1)
improvement in our understanding of the precise molecular and
pathophysiological mechanisms of cardiotoxicity; (2) improve-
ment in risk prediction that allows targeted treatment and
avoidance of unnecessarily burdensome therapies for patients
most likely to develop cardiotoxicity; (3) randomized controlled
trials comparing surveillance frequency for cardiotoxicity preven-
tion and superiority of different treatment strategies on minimiz-
ing and preventing cardiovascular complications. The widely
advocated precision medicine encompassing “big data” and omics
including pharmacogenetics-pharmacogenomics127, 128 would ﬁt
perfectly well to the urgently needed area of cardio-oncology
research and clinical care. Finally, the multidisciplinary approach of
cardio-oncology service with close collaborations among oncolo-
gists, cardiologists, and other allied health care professionals will
be essential in the development and promotion of clinical care
models to improve long-term outcomes of cancer treatments and
cancer survivors.
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